CBS and chronic myelogenous leukemia, BCR-ABL1 positive: Inhibition of CBS reduced the malignancy of CML, accompanied by alterations in bone marrow mononuclear cells, apoptosis, cell-cycle progression, and migration in K562 cells and tumor xenografts.